Skip to main content
Clinical Trials/NCT00183755
NCT00183755
Completed
Not Applicable

Neuroimaging Studies of Reward Processing in Depression

Mclean Hospital3 sites in 1 country87 target enrollmentApril 2005
ConditionsDepression

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Depression
Sponsor
Mclean Hospital
Enrollment
87
Locations
3
Primary Endpoint
Performance on Monetary Incentive Delay task
Status
Completed
Last Updated
12 years ago

Overview

Brief Summary

This study will examine brain responses associated with reinforcement and reward tasks in individuals with major depressive disorder (MDD).

Detailed Description

Major depressive disorder (MDD) is a severe form of depression that can significantly interfere with an individual's thoughts, behavior, mood, and physical health. People who suffer from MDD may experience anhedonia, or the inability to gain pleasure from normally pleasurable experiences. Such individuals do not respond to motivational rewards in the same way as do individuals who are not depressed. Anhedonia has been recognized as a core symptom of depression and it is not always remedied with antidepressant medication. Abnormal brain activity and processing may be the underlying cause of depression and specifically anhedonia. A better understanding of the brain mechanisms of depression may lead to the development of new effective medications or psychological treatments. Event-related potential (ERP), which measures electrical activity in the brain, and functional magnetic resonance imaging (fMRI), which uses scanned images to illustrate changes in brain activity, are two techniques that can identify abnormal areas of brain processing. The purpose of this study is to use ERP and fMRI to compare brain activity that is related to reward processing in individuals with MDD versus individuals without MDD. This study will consist of 3 study visits; visits will be scheduled as close together as possible. At the first study visit, potential participants will be assessed with the SCID (Structured Clinical Interview for DSM-IV), which will identify individuals with the diagnostic criteria for MDD. A control group of non-depressed individuals will also be enrolled in the study. During the second and third study visits, participants will take part in a monetary reinforcement reward task followed by a signal detection reward task. Brain activity of all participants will be monitored during both tasks. During the second study visit, ERP will be used; during the third study visit, fMRI will be used. Demographic information will also be collected, and participants will complete several standardized questionnaires to assess mood. Some participants will be asked to return after eight weeks to complete the fMRI and EEG sessions again. Those who do complete all five sessions will be awarded a bonus.

Registry
clinicaltrials.gov
Start Date
April 2005
End Date
April 2009
Last Updated
12 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Diego A. Pizzagalli

Associate Professor, Harvard Medical School

Mclean Hospital

Eligibility Criteria

Inclusion Criteria

  • Right-handed
  • Agrees to use an effective form of contraception throughout the study
  • Inclusion Criteria for Depressed Participants:
  • Meets overall inclusion criteria
  • Meets DSM-IV diagnosis criteria for major depressive disorder
  • Score of at least 16 on the 21-item HAM-D scale

Exclusion Criteria

  • Left-handed or ambidextrous
  • Claustrophobic
  • Neurological or medical illness (e.g., attention deficit hyperactivity disorder, head injury, loss of consciousness, seizures)
  • Exclusion Criteria for Depressed Participants:
  • Meets any of the overall exclusion criteria
  • Has been treated with electroconvulsive therapy within 6 months of study entry
  • Has taken any benzodiazepine medications for at least 2 weeks prior to study entry and discontinued use of the medication for reasons other than participating in the study
  • Has taken any dopaminergic medications (including methylphenidate) or neuroleptics for at least 6 months prior to study entry and discontinued use of the medication for reasons other than participating in the study
  • Has taken any fluoxetine medications for at least 6 weeks prior to study entry and discontinued use of the medication for reasons other than participating in the study
  • Has taken any medications that may have antidepressant properties (including some herbal supplements) within 2 weeks of study entry

Outcomes

Primary Outcomes

Performance on Monetary Incentive Delay task

Time Frame: Given once during the second session for half an hour, and once during the third session for half an hour

This task features balanced incentive delivery and analytic strategies designed to identify activity specific to anticipation or consumption of incentives.

Signal detection reward task

Time Frame: Given once during the second session for fifteen minutes, and once during the third session for fifteen minutes

This reward task provides an objective assessment of hedonic capacity. Due to the probabilistic nature of the task, participants cannot infer which stimulus is more advantageous based on the outcome of single trials but need to integrate reinforcement history over time to optimize behavior.

Study Sites (3)

Loading locations...

Similar Trials